High-Standard, High-Quality Raw Material System: The In-House Manufacturing Foundation for CrystoGen™ Microcrystalline Spheres

In pet intestinal nutrition, what truly determines stability is not merely whether the raw materials themselves “have functional properties,” but rather the ability to understand and control the raw-material production process.

Since its inception, NEWGEN has adhered to the principle of “research-driven innovation with manufacturing as the foundation,” consistently pursuing independent R&D and building its own production lines.

Our current product portfolio encompasses enzymes, probiotics, functional polysaccharides, and a wide array of bioactive ingredients. Leveraging our proprietary manufacturing platform, we engage in the design, production, and optimization of raw materials at the very source, ensuring that these ingredients are inherently tailored to support subsequent structured delivery systems and formulation applications.

Manufacturing capability determines the system’s upper limit.

 

The CrystoGen™ raw-material system is built on in-house production, with its core advantage lying in the controllability of critical process steps. This controllability is reflected in the fermentation process, the enzyme-production pathway, and the concurrent development of functional bioactive compounds, all aimed at establishing a stable foundation for subsequent structured applications.

During the manufacturing stage, raw materials are carefully evaluated for their compatibility with CrystoGen™ pet microcrystalline spheres in terms of stability, drug-loading capacity, and subsequent structural compatibility, ensuring that these spheres are better suited for multi-layer encapsulation and targeted release rather than merely being passively adapted during the formulation stage.

—Representative Ingredients—

Lactase (β-galactosidase)

 

Alpha-galactosidase

 

DPP IV

 

A comprehensive enzyme product portfolio:

NEWGEN boasts a comprehensive enzyme formulation portfolio, featuring well-defined enzyme sources with high activity, making it suitable for a wide range of applications and dosage forms, including pet powders, tablets, liquids, freeze-dried products, gummies, and chewable candies.

 

Probiotics: Considering Formulation Compatibility from the Fermentation Stage

Unlike enzymes, probiotics are more susceptible to the gastrointestinal environment. Leveraging its proprietary fermentation platform, NEWGEN places a strong emphasis on maintaining optimal probiotic cell integrity and ensuring structural compatibility throughout the production process, thereby achieving greater consistency and bioavailability of the strains prior to their incorporation into the CrystoGen™ microcrystal delivery system.

 

Lactobacillus acidophilus HN07: Antioxidant, Anti-inflammatory, and Alleviation of Colitis Symptoms

 

 

Lactobacillus acidophilus ATCC 4356: Antioxidant Activity and Reduction of Metabolism-Related Inflammatory Burden

 

Lactobacillus fermentum PDD-1: Antioxidant, Liver Protection, and Gut Microbiota Modulation

Streptococcus thermophilus GYX-8: Antioxidant activity, modulation of the gut microbiota, and elevation of short-chain fatty acid levels.

 

 

Specifically formulated for the digestive tracts of dogs and cats.

Compared with humans, the digestive systems of dogs and cats differ markedly in gastric acid strength, feeding rhythms, and the digestion process itself. This means that many ingredient or formulation designs that are effective in other animal species may not be directly suitable for long-term pet nutrition.

Throughout the development of pet-grade raw materials and formulation design at NEWGEN, the actual digestive pathways of dogs and cats have always served as the central reference point. It is precisely on this premise that the CrystoGen™ microcrystalline sphere system was designed from the outset with pet applications in mind, ensuring that the raw materials, structural design, and formulation closely align with the long-term nutritional needs of dogs and cats.

 

 

Starting from the raw materials, tailored to the formulation.

NEWGEN firmly believes that formulation design is only truly actionable—and not merely theoretical—when raw materials are integrated into the structural and release logic from the very outset of the manufacturing process.

The CrystoGen™ pet microcrystal bead system is built precisely on this premise: aligning raw materials, product structure, and formulation from the very outset to converge on a single objective, rather than resorting to passive adjustments during the application phase.

Based on this raw-material and formulation foundation, diverse enteral nutrition formulations can be systematically developed and designed, validated, and optimized to achieve specific functional objectives. Moreover, the system itself exhibits excellent dosage-form compatibility, supporting a wide range of product formats, including powders, granules, tablets, and capsules.

Leveraging its proprietary raw-material system and validation platform, NEWGEN is able to provide partners with a comprehensive end-to-end support pathway—spanning raw materials, premixes, and finished products—ensuring that formulations move beyond the conceptual stage and are reliably implemented in real-world feeding scenarios.

 

 

 

—About NEWGEN—

About Us

 

Ningbo Xinyao Marine Biotechnology Co., Ltd. is located in Xiangshan County, Ningbo City. Founded in 2013 by Dr. Zhu Hui, a U.S.-trained immunology expert who returned to China, the company is a high-tech enterprise. Grounded in marine biological resources and leveraging synthetic biology technologies, Xinyao develops natural bioactive macromolecular products derived from marine organisms, with the mission of delivering intestinal nutrition and health solutions and revitalizing nutrition and health services.

 

 

The company is among the world’s leaders in the fields of marine polysaccharides, marine enzyme preparations, and intestinal microbiota. Leveraging its strong capabilities and cutting-edge technologies in marine biopharmaceuticals, the company has undertaken numerous national, provincial, and municipal R&D projects, including the National 13th Five-Year Plan Project for Marine Innovation Development and Demonstration, the Ningbo Municipal “2025 Science and Technology Breakthrough” Major Special Project, and the Ningbo Municipal “Challenge-Based Recruitment” Major Special Project, among others.

 

 

The company has obtained numerous quality management system certifications, including ISO 22000:2015 for food safety management, ISO 9001:2015 for quality management, HACCP for food safety, as well as Kosher, Halal, and NSF-CGMP certifications. It is a member of several international associations, such as the International Probiotics Association (IPA) and the Enzyme Technical Association (ETA), and has received multiple provincial- and municipal-level awards for technological innovation, including the Third Prize of the China Council for the Promotion of International Trade Science and Technology Award, the Second Prize of the China Invention Association, and the Third Prize of the Ningbo Science and Technology Progress Award. The company places great emphasis on intellectual property protection; as of 2023, it has filed more than 70 patent applications and been granted 36 patents, including 23 invention patents.